Cargando…

Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection

A group of 110 patients from the West Bohemian region who had been infected with COVID-19 was monitored for the purposes of this study. We focused on cases of mild or moderate COVID-19; statistically the most likely to occur. Day zero was defined as the day on which a positive PCR test was first est...

Descripción completa

Detalles Bibliográficos
Autores principales: Šimánek, Václav, Pecen, Ladislav, Řezáčková, Hana, Topolčan, Ondřej, Fajfrlík, Karel, Sedláček, Dalibor, Šín, Robin, Bludovská, Monika, Pazdiora, Petr, Slouka, David, Kučera, Radek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534661/
https://www.ncbi.nlm.nih.gov/pubmed/34679613
http://dx.doi.org/10.3390/diagnostics11101915
_version_ 1784587605308866560
author Šimánek, Václav
Pecen, Ladislav
Řezáčková, Hana
Topolčan, Ondřej
Fajfrlík, Karel
Sedláček, Dalibor
Šín, Robin
Bludovská, Monika
Pazdiora, Petr
Slouka, David
Kučera, Radek
author_facet Šimánek, Václav
Pecen, Ladislav
Řezáčková, Hana
Topolčan, Ondřej
Fajfrlík, Karel
Sedláček, Dalibor
Šín, Robin
Bludovská, Monika
Pazdiora, Petr
Slouka, David
Kučera, Radek
author_sort Šimánek, Václav
collection PubMed
description A group of 110 patients from the West Bohemian region who had been infected with COVID-19 was monitored for the purposes of this study. We focused on cases of mild or moderate COVID-19; statistically the most likely to occur. Day zero was defined as the day on which a positive PCR test was first established. The mean length of observation was 6.5 months, the maximum length 12 months. The first blood samples were taken from a smaller cohort during the 1–3 months following the first positive PCR test. We assumed that SARS-CoV-2 antibodies would be present during this period and therefore a limited number of samples were taken for the purpose of detecting antibodies. More samples were collected, starting 4 months after the first positive PCR test. A subsequent set of blood samples were drawn, mostly 6 months after the first ones. Our study confirmed the presence of total IgG SARS-CoV-2 antibodies up to 1 year after the onset of the disease. The peak of antibody production was observed in the third month after the first positive PCR test. A mathematical estimate of the median duration of antibody positivity was calculated to be 18 months from the onset of the COVID-19 infection.
format Online
Article
Text
id pubmed-8534661
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85346612021-10-23 Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection Šimánek, Václav Pecen, Ladislav Řezáčková, Hana Topolčan, Ondřej Fajfrlík, Karel Sedláček, Dalibor Šín, Robin Bludovská, Monika Pazdiora, Petr Slouka, David Kučera, Radek Diagnostics (Basel) Article A group of 110 patients from the West Bohemian region who had been infected with COVID-19 was monitored for the purposes of this study. We focused on cases of mild or moderate COVID-19; statistically the most likely to occur. Day zero was defined as the day on which a positive PCR test was first established. The mean length of observation was 6.5 months, the maximum length 12 months. The first blood samples were taken from a smaller cohort during the 1–3 months following the first positive PCR test. We assumed that SARS-CoV-2 antibodies would be present during this period and therefore a limited number of samples were taken for the purpose of detecting antibodies. More samples were collected, starting 4 months after the first positive PCR test. A subsequent set of blood samples were drawn, mostly 6 months after the first ones. Our study confirmed the presence of total IgG SARS-CoV-2 antibodies up to 1 year after the onset of the disease. The peak of antibody production was observed in the third month after the first positive PCR test. A mathematical estimate of the median duration of antibody positivity was calculated to be 18 months from the onset of the COVID-19 infection. MDPI 2021-10-16 /pmc/articles/PMC8534661/ /pubmed/34679613 http://dx.doi.org/10.3390/diagnostics11101915 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Šimánek, Václav
Pecen, Ladislav
Řezáčková, Hana
Topolčan, Ondřej
Fajfrlík, Karel
Sedláček, Dalibor
Šín, Robin
Bludovská, Monika
Pazdiora, Petr
Slouka, David
Kučera, Radek
Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection
title Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection
title_full Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection
title_fullStr Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection
title_full_unstemmed Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection
title_short Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection
title_sort long-term monitoring of the antibody response to a sars-cov-2 infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534661/
https://www.ncbi.nlm.nih.gov/pubmed/34679613
http://dx.doi.org/10.3390/diagnostics11101915
work_keys_str_mv AT simanekvaclav longtermmonitoringoftheantibodyresponsetoasarscov2infection
AT pecenladislav longtermmonitoringoftheantibodyresponsetoasarscov2infection
AT rezackovahana longtermmonitoringoftheantibodyresponsetoasarscov2infection
AT topolcanondrej longtermmonitoringoftheantibodyresponsetoasarscov2infection
AT fajfrlikkarel longtermmonitoringoftheantibodyresponsetoasarscov2infection
AT sedlacekdalibor longtermmonitoringoftheantibodyresponsetoasarscov2infection
AT sinrobin longtermmonitoringoftheantibodyresponsetoasarscov2infection
AT bludovskamonika longtermmonitoringoftheantibodyresponsetoasarscov2infection
AT pazdiorapetr longtermmonitoringoftheantibodyresponsetoasarscov2infection
AT sloukadavid longtermmonitoringoftheantibodyresponsetoasarscov2infection
AT kuceraradek longtermmonitoringoftheantibodyresponsetoasarscov2infection